
BACKGROUND
Alnylam is the world’s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market.
REQUIREMENTS FULFILLED BY SKYLAND PIMS®
- Data sharing among internal teams and CMOs
- Lower risk compared to reliance on in-house database
- FDA validatable environment
- End-to-end manufacturing and quality data platform across 2 commercial products and 6 clinical stage products
- 21 CFR Part II compliant
- Centralized, higher data integrity platform
- Use of PIMS with other analytics tools e.g. JMP
- Compatible with current and future automation payments
- Higher efficiencies through automated work processes
- Reduced risk of non-compliance
- Knowledge sharing across complete portfolio of clinical and commercial products
